Literature DB >> 31662571

Anterior Pelvic Exenteration for Chemo-irradiated Non-diethylstilbestrol Exposed Clear Cell Vaginal Cancer.

Nicolae Bacalbasa1,2,3, Irina Balescu4, Mihaela Vilcu1,2, Simona Dima3, Iulian Brezean1,2.   

Abstract

BACKGROUND/AIM: Clear cell vaginal adeno-carcinomas are rare tumors occurring in women which are usually treated by chemo radiotherapy with good outcomes. However, in certain cases, this treatment is not associated with complete response and a further surgery is needed. CASE REPORT: We present the case of a 38-year-old patient diagnosed with stage IVA clear cell vaginal cancer who had been previously submitted to radio chemotherapy and in whom the lesion persisted after the oncological treatment; therefore, the patient was proposed for surgery with curative intent. The tumor was resected by performing an anterior pelvic exenteration with good outcomes, the patient being discharged in the seventh postoperative day. At one-year follow-up the patient remains free of recurrent disease.
CONCLUSION: Pelvic exenteration with curative intent might be the option of choice for persistent locally advanced clear cell vaginal cancer. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Clear cell vaginal cancer; anterior pelvic exenteration; neoadjuvant chemo-irradiation

Mesh:

Substances:

Year:  2019        PMID: 31662571      PMCID: PMC6899136          DOI: 10.21873/invivo.11737

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  15 in total

1.  Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks.

Authors:  A Hanselaar; M van Loosbroek; O Schuurbiers; T Helmerhorst; J Bulten; J Bernhelm
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

2.  Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas).

Authors:  A L Herbst; R E Scully
Journal:  Cancer       Date:  1970-04       Impact factor: 6.860

3.  Multimodality treatment of adenocarcinoma of the vagina Stage IV: potential for cure.

Authors:  A Abitbol; M J Straus; A Sedlis; M Davidian
Journal:  Gynecol Oncol       Date:  1983-10       Impact factor: 5.482

4.  The National Cancer Data Base report on cancer of the vagina.

Authors:  W T Creasman; J L Phillips; H R Menck
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

5.  Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.

Authors:  Dezheng Huo; Diane Anderson; Julie R Palmer; Arthur L Herbst
Journal:  Gynecol Oncol       Date:  2017-07-06       Impact factor: 5.482

6.  Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Irina Balescu
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

7.  Use of Inflated Foley Catheters to Prevent Early Empty Pelvis Complications Following Pelvic Exenteration.

Authors:  Nicolae Bacalbasa; Dana Tomescu; Irina Balescu
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

8.  Partial Cystectomy with Distal Ureteral Resection and Re-implantation for Locally Invasive Cervical Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Dana Tomescu
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

9.  Clear cell adenocarcinoma of the vagina in a young female, treated by combination chemotherapy (local and systemic chemotherapy), complicated with chromosomal abnormality.

Authors:  H Tanaka; T Tabata; H Yanase; M Nishiyama; T Yamawaki; H Taniguchi; N Toyoda
Journal:  Gynecol Oncol       Date:  1994-11       Impact factor: 5.482

10.  Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report.

Authors:  Yuji Ikeda; Katsutoshi Oda; Hiroyuki Aburatani; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  Gynecol Oncol Rep       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.